Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Daniel W. Lee, III, MD, Nirali N Shah, MD, Maryalice Stetler-Stevenson, MD, PhD, Marianna Sabatino, Cindy Delbrook, RN, Kelly Richards, RN, James N Kochenderfer, M.D., Steven A. Rosenberg, M.D., Ph.D., David Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2013) 122 (21): 68.

https://doi.org/10.1182/blood.V122.21.68.68

Published: 2013

Journal Articles

Early Clinical Experience of aAPC Activated NK-DLI Following Allogeneic PBSCT in Pediatric Solid Tumor Patients.

Kristin Baird, MD, Terry J Fry, MD, Melinda Merchant, MD, PhD, Kelly Richards, RN, Cynthia Delbrook, RN, Alan S Wayne, MD, Crystal L Mackall, MD

Blood (2012) 120 (21): 3013.

https://doi.org/10.1182/blood.V120.21.3013.3013

Published: 2012

Journal Articles

Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer

Nirali N Shah, MD, Melinda Merchant, MD, PhD, Diane Cole, Kelly Richards, RN, Cindy Delbrook, RN, Brigitte C Widemann, MD, Alan S Wayne, MD

Blood (2012) 120 (21): 1497.

https://doi.org/10.1182/blood.V120.21.1497.1497

Published: 2012

Journal Articles

Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD, PhD, Marianna Sabatino, MD, Barbara Tumaini, MS, Kelly Richards, RN, Cindy Delbrook, RN, James N Kochenderfer, M.D., Steven A. Rosenberg, David Stroncek, MD, Crystal L Mackall, MD, Alan S Wayne, MD

Blood (2012) 120 (21): 2609.

https://doi.org/10.1182/blood.V120.21.2609.2609

Published: 2012

Journal Articles

A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies and Post-Transplant Relapse

Nirali N Shah, MD, David Loeb, MD, PhD, Hahn Khuu, MD, David Stroncek, MD, Mark Raffeld, MD, Cindy Delbrook, RN, Kelly Richards, RN, Kristin Baird, MD, Jason Levine, MD, Susan F. Leitman, MD, Crystal L Mackall, MD, Terry J Fry, MD, Alan S Wayne, MD

Blood (2011) 118 (21): 3055.

https://doi.org/10.1182/blood.V118.21.3055.3055

Published: 2011

Journal Articles

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Alan S Wayne, MD, Deepa Bhojwani, MD, Lewis B. Silverman, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PhD, Nirali N Shah, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Manuela Buzoianu, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Ramy Ibrahim, MD, Ira Pastan, MD

Blood (2011) 118 (21): 248.

https://doi.org/10.1182/blood.V118.21.248.248

Published: 2011

Journal Articles

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Alan Wayne, MD, Deepa Bhojwani, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PHD, Lewis B. Silverman, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Robert J. Lechleider, MD, Ira Pastan, MD

Blood (2010) 116 (21): 3246.

https://doi.org/10.1182/blood.V116.21.3246.3246

Published: 2010

NARROW

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Early Clinical Experience of aAPC Activated NK-DLI Following Allogeneic PBSCT in Pediatric Solid Tumor Patients.

Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer

Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies and Post-Transplant Relapse

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Email alerts

ASH Publications

American Society of Hematology

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Early Clinical Experience of aAPC Activated NK-DLI Following Allogeneic PBSCT in Pediatric Solid Tumor Patients.

Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer

Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies and Post-Transplant Relapse

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only